Genmab A/S (OTCMKTS:GNMSF) Short Interest Up 98.0% in May

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 146,300 shares, a growth of 98.0% from the April 30th total of 73,900 shares. Approximately 0.2% of the company's shares are short sold. Based on an average daily volume of 3,400 shares, the short-interest ratio is currently 43.0 days.

Genmab A/S Price Performance

Genmab A/S stock traded down $2.00 during trading hours on Monday, reaching $207.75. The stock had a trading volume of 84 shares, compared to its average volume of 2,846. The company has a fifty day simple moving average of $196.81 and a 200-day simple moving average of $205.15. Genmab A/S has a 52 week low of $170.00 and a 52 week high of $292.80. The stock has a market cap of $13.73 billion, a PE ratio of 11.86 and a beta of 1.02.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $3.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $1.17. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%. The company had revenue of $765.14 million for the quarter, compared to analysts' expectations of $761.09 million.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.